NeoGenomics (NEO) Tops Q2 EPS by 6c

NeoGenomics (NASDAQ: NEO) reported Q2 EPS of ($0.04), $0.06 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $87 million versus the consensus estimate of $86.55 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Morgan Stanley upgrades CDW on stronger AI-driven server demand